Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07114874 · ClinicalTrials.gov registry record · Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07114874: Recruiting Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.
NCT07114874 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 800 participants, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (270% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07114874, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Conditions Studied
Interventions
- DRUG NBI-1117568
Study Locations (20)
California
- Neurocrine Clinical Site - Culver City
- Neurocrine Clinical Site - Garden Grove
- Neurocrine Clinical Site - Pico Rivera
- Neurocrine Clinical Site - Riverside
- Neurocrine Clinical Site - San Diego
- Neurocrine Clinical Site - Sherman
- Neurocrine Clinical Site - Torrance
Georgia
- Neurocrine Clinical Site - Atlanta
- Neurocrine Clinical Site - Atlanta
- Neurocrine Clinical Site - Decatur
- Neurocrine Clinical Sites - Peachtree Corners
Florida
- Neurocrine Clinical Site - Hollywood
- Neurocrine Clinical Site - Miami Lakes
Arkansas
- Neurocrine Clinical Site - Little Rock
Illinois
- Neurocrine Clinical Site - Chicago
Maryland
- Neurocrine Clinical Site - Gaithersburg
Massachusetts
- Neurocrine Clinical Site - Watertown
Missouri
- Neurocrine Clinical Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2031-12 |
| Phase | Phase 3 |
What NCT07114874 shows while recruiting
NCT07114874 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 216-participant average among 315 other Schizophrenia trials with a reported enrollment target (270% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which NBI-1117568 is the first listed.
NCT07114874 names 20 study sites across 10 states, led by California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT07114874 about?
NCT07114874 is a clinical study titled "NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia". This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
What is the current status of trial NCT07114874?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-07-11. Estimated completion is 2031-12.
What conditions does trial NCT07114874 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07114874?
The interventions under investigation include: NBI-1117568 (DRUG).
Who is sponsoring clinical trial NCT07114874?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07114874 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07114874's enrollment target sits among peer trials
800 13th of 315 higher than 302 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
-
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI